-
Professor Ying Zhitao: The road ahead is also bright, improve the efficacy of CAR-T, solve the dilemma of CAR-T cell therapy, and the 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
On the occasion of the "7th Anti-Leukemia and Lymphoma International Summit Forum and CSCO Leukemia & Lymphoma Expert Committee Tour - Harbin Station", Yimaitong is honored to invite Professor Ying Zhitao of Peking University Cancer Hospital to be interviewed to introduce the current status of CAR-T cell therapy in lymphoma treatment, and talk about the achievements and future exploration directions of the lymphoma department of Peking University Cancer Hospital (Beiwei).
-
Professor Ying Zhitao: The road ahead is also bright, improve the efficacy of CAR-T, solve the dilemma of CAR-T cell therapy, and the 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
On the occasion of the "7th Anti-Leukemia and Lymphoma International Summit Forum and CSCO Leukemia & Lymphoma Expert Committee Tour - Harbin Station", Yimaitong is honored to invite Professor Ying Zhitao of Peking University Cancer Hospital to be interviewed to introduce the current status of CAR-T cell therapy in lymphoma treatment, and talk about the achievements and future exploration directions of the lymphoma department of Peking University Cancer Hospital (Beiwei).
-
The world found the second case of AIDS who healed without treatment
Time of Update: 2021-12-06
In October of this year, Gilead and Merck announced that they will start a phase II clinical study to evaluate the weekly islatravir/lenacapavir oral combination therapy among HIV-infected patients who are virologically suppressed after antiretroviral therapy.
-
How should the FDA reshape the accelerated approval process
Time of Update: 2021-11-04
A recent study showed that four cancer immunotherapies approved by the FDA (Accelerated Approval) were withdrawn due to invalid confirmatory trials, and Medicare spent on these invalid therapies between 2017 and 2019.
-
Share the leaflet of the balsalazide drug
Time of Update: 2021-07-07
For middle-aged and elderly people, taking drugs can also prevent the occurrence of diseases.
The body is healthier, what is the content of the balsalazide sodium drug instruction?
What are the contents of the instructions for the balsalazide sodium drug?
-
Pfizer and others go forward and continue AD research and development stagnant, can Bojian Aducanumab stand out
Time of Update: 2021-06-17
Similarly, in the face of such urgent patient demand and market vacancies, in addition to the approval of the ninth phase one developed by Green Valley Pharmaceuticals, currently domestic companies including Hengrui, Dongyang Sunshine, Hisun and other companies have joined the track.
-
The longest follow-up study data in the phase III clinical trial of first-line treatment of lung cancer in tumor immunotherapy
Time of Update: 2020-10-15
"The KEYNOTE-024 trial is the only phase III clinically proven five-year increase in the first-line treatment of advanced lung cancer in immunotherapy," said Professor Lu Wei, Director of Oncology At Shanghai Jiaoxuan University's Affiliated Chest Hospital.
-
Forecast! Trends in Chinese medicine tablets in the next five years
Time of Update: 2020-05-28
Recently, the company received a giant business cooperation audit, mainly related to the Chinese medicine traceability system cooperation matters happened to see an article in the morning in the circ
-
Announcement of the State Administration of pharmaceutical packaging materials on the related review and approval of pharmaceutical excipients and drugs (2016 No. 134
Time of Update: 2016-08-11
Source: CFDA 2016-8-11 to implement the opinions of the State Council on the reform of the review and approval system for pharmaceutical and medical devices (GF [2015] 44) No.), simplify the drug appr
